Changes in Beneficial Ownership · 4
Gilead Sciences, Inc.
GILDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1789590469.xml
Filing details
- Report period
- 2026-09-15
- Issuer
- GILEAD SCIENCES, INC.
- Issuer CIK
- 0000882095
- Trading symbol
- GILD
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Mercier Johanna
- Reporting owner CIK
- 0001782135
- Relationship
- Officer
- Officer title
- Chief Comm & Corp Aff Officer
- Address
- GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-15 | S · Form 4[F1] | 1,600 | D | 143.6917[F2] | 118,084 | D |
| Common Stock | 2026-09-15 | S · Form 4[F1] | 800 | D | 144.4569[F3] | 117,284 | D |
| Common Stock | 2026-09-15 | S · Form 4[F1] | 600 | D | 145.29 | 116,684 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.↩ 1↩ 2↩ 3
- F2
- Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.↩ 1
- F3
- Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.↩ 1
Signature 1
- Signed
- /s/ Amy Kim by Power of Attorney for Johanna Mercier
- Date
- 2026-09-16
Company context
Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.